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The neurobiological basis of autism spectrum disorder (ASD) remains poorly understood. 
Given the role of CD38 in social recognition through oxytocin (OT) release, we 
hypothesized that CD38 may play a role in the etiology of ASD. Here, we first examined 
the immunohistochemical expression of CD38 in the hypothalamus of post-mortem brains 
of non-ASD subjects and found that CD38 was colocalized with OT in secretory neurons. 
In studies of the association between CD38 and autism, we analyzed 10 single nucleotide 
polymorphisms (SNPs) and mutations of CD38 by re-sequencing DNAs mainly from a 
case-control study in Japan, and Caucasian cases mainly recruited to the Autism Genetic 
Resource Exchange (AGRE). The SNPs of CD38, rs6449197 (p<0.040) and rs3796863 
(p<0.005) showed significant associations with a subset of ASD (IQ>70; designated as 
high-functioning autism (HFA)) in the U.S. 104 AGRE family trios, but not with Japanese 
188 HFA subjects. A mutation that caused tryptophan to replace arginine at amino acid 
residue 140 (R140W; (rs1800561, 4693C>T)) was found in 0.6%-4.6% of the Japanese 
population and was associated with ASD in the smaller case-control study. The SNP was 
clustered in pedigrees in which the fathers and brothers of T-allele-carrier probands had 
ASD or ASD traits. In this cohort OT plasma levels were lower in subjects with the T allele 
than in those without. One proband with the T allele who was taking nasal OT spray 
showed relief of symptoms. The two variant CD38 poloymorphysms tested may be of 
interest with regard of the pathophysiology of ASD. 
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1. Introduction 
        Autism spectrum disorder (ASD) is a neurodevelopmental disease manifesting in 
childhood but extending through to adulthood. The disorder is more common than 
previously supposed, with a worldwide frequency of >0.6% (Honda et al., 2005; Baird et 
al., 2006; Williams et al., 2006). The region with the maximum reported rate (3% of births) 
is the Nagoya/Hamamatsu region in Japan (Sumi et al., 2006). ASD can be sporadic or 
familial and is far more common in males than in females (Zhao, 2007). Because ASD is 
etiologically heterogeneous and forms a continuum, it is likely to involve many genes 
(Sutcliffe, 2008; Levitt and Campbell, 2009). De novo mutations and copy number 
variations (CNVs) are reported in a small fraction of ASD cases (Sebat et al., 2007; Glesser 
et al., 2009), but common variants also underlie the disease (Wang et al., 2009), and a 
unified mechanism for both forms of genetic inheritance has been proposed (Zhao et al., 
2007). 
  Oxytocin (OT) is secreted into the brain by hypothalamic neuronal dendrites and 
plays important roles in social recognition and memory (Insel & Fernald, 2004; Takayanagi 
et al., 2005; Donaldson et al., 2008; Neumann, 2008). This hormone mediates behavioral 
effects, such as pair bonding, mate guarding, and parental care in rodents (Ferguson et al., 
2000; Ludwig and Leng, 2006; Campbell, 2008) and may be involved in romantic love, 
trust, and fear in humans (Koshfeld et al., 2005; Zeki, 2007; Domes et al., 2007; Ditzen et 
al., 2009). Recently, evidence has accumulating to suggest that the polymorphisms of 
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multiple OT-related genes are associated with ASD (Wu et al., 2005; Jacob et al., 2007; 
Ebstein et al. 2008; Gregory et al., 2009; Wermter et al., 2009). 
 
    Peripheral or nasal administration of OT facilitates social recognition and trust in 
healthy humans (Guastella et al., 2008a and b, 2009; Ditzen et al., 2009) and increases eye 
contact and recognition in autistic subjects (Hollander et al., 2007; Yamasue et al., 2009). 
Those observations are based mostly on a small number of administrations, and the effects 
of long-term OT treatment on human social behavior in ASD patients is unknown.  
Human CD38 is a type II transmembrane antigen (Malavasi et al., 2008). The 
CD38 gene consists of 8 exons on 4p15 (Nakagawa et al., 1995) and spans a genomic 
stretch of 70.51 kb. The mRNA contains 1227 bases, and single nucleotide polymorphisms 
(SNPs) have been reported (Nata et al., 1997; Yagui et al., 1998; Ebstein et al., 2009; see 
Fig. 2A). CD38 has been studied extensively because it is a reliable negative prognostic 
marker for chronic lymphocytic leukemia (Deaglio et al., 2008). CD38 is expressed in the 
brain (Lee, 2001; Higashida et al., 2007) and can catalyze the formation of cyclic 
ADP-ribose (cADPR) from NAD+ (Lee, 2001; Guse, 2005; Malvasi et al., 2008). cADPR 
mobilizes Ca2+ from intracellular Ca2+ stores, thus acting as a second messenger (Lee, 
2001). Little was known about the CD38-dependent cADPR/Ca2+ signaling pathway in the 
brain until recent studies in our laboratory. They showed that CD38 regulates OT secretion 
in the mouse hypothalamus and posterior pituitary, which is critical for mouse social 
behavior (Jin et al., 2007; Liu et al., 2008). The precise role of CD38 in the human 
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hypothalamus, however, has not been clarified. 
 
As OT seems to be an important factor for the understanding of ASD, we examined 
the relationships among human CD38 polymorphisms and mutations in Japanese, Korean, 
and Caucasian subjects. We identified two functional polymorphisms in subgroups: ASD 
and high-functioning autism (HFA) based on IQ (>70 classified as HFA). We measured the 
carrier’s serum OT levels and examined each subject for ASD. Here, we also discuss the 
possibility of treating ASD patients who have a SNP that lowers OT levels by intranasal 
administration of OT.  
 
2. Materials and Methods  
2.1. CD38 expression and immunohistochemistry 
We measured CD38 mRNA levels by the semi-quantitative or real-time quantitative 
RT-PCR method (Jin et al., 2007) using commercially available total RNAs from various 
regions of the human brain. Control human brain tissues were obtained from archival 
blocks in the Departments of Pathology at the University of California San Francisco and 
Kanazawa University Graduate School of Medicine. The use of this tissue followed the 
institutional guidelines established by the Committee on Human Research (CHR) in both 
universities. The immunofluorescent stainings for human CD38 and OT were performed 
according to the procedures described previously (Zhang et al., 2007). Briefly, sections of 
the hypothalamus were treated with antigen retrieval protocol (0.01M citrate acid buffer 
pH 6.0, plus heating for 121°C for 5 min). The sections were then incubated with primary 
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antibody against human CD38 (1:50, sc-7325, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and OT (1:500, AB911, Chemicon, Billerica, MA, USA) overnight in room 
temperature, followed by washing in Tris-buffered saline (TBS), and incubation with 
secondary antibodies that were conjugated with Alexa 488 or Alexa 568 (1:300, A11001 
and A11011; Invitrogen) for 1 h in room temperature. Images for the co-localization of 
CD38 and OT in the paraventricular nucleus of the hypothalamus were captured using a 
Leica confocal microscope (TCS SP, Bannockburn, IL, USA) and imported into the 
Photoshop software.  
 
2.-2. Participants 
The participants consisted of cohorts organized by the 
Osaka-Hamamatsu-Kanazawa University Joint Research Centers for Child Mental 
Development, the Kanazawa University COE Program, the Core Research for Evolutional 
Science and Technology Program in Japan, which includes DNA samples collected at the 
University of Tokyo (Table 1). Three hundred and fifty-seven ASD subjects were recruited 
from outpatient psychiatry or pediatric clinics of each university hospital. All subjects 
fullfilled the DSM-IV criteria for autistic disorder. The diagnoses were made by two 
experienced child psychiatrists through interviews and clinical record reviews, and the 
subjects had no apparent physical anomalies. We also recruited patients’ parents, 
grandparents, siblings, and other relatives from 322 families. The controls consisted of 
unrelated healthy Japanese volunteers—315 from the first cohort and 417 from the second. 
We recruited adult controls mainly from among hospital and facility staff and medical 
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schools, and age-matched children as controls. In the Japanese cohorts, all subjects resided 
in Kanazawa, Hamamatsu/Nagoya, Tokyo, or Osaka, Japan, and all patients and controls 
were Japanese with no non-Japanese parents or grandparents. Two experienced child 
psychiatrists independently confirmed the diagnosis of ASD for most patients by 
semi-structured behavior observation and interviews with the subjects and their parents. At 
the interview with the parents, which was helpful in the evaluation of autism-specific 
behaviors and symptoms, the examiner used one of the following instruments: the Asperger 
Syndrome Diagnostic Interview (Gillberg et al., 2001), Autism Diagnostic 
Interview-Revised (ADI-R; Lord et al., 1994), Pervasive Developmental Disorders Autism 
Society Japan Rating Scale (2006), or Diagnostic Interview for Social and Communication 
Disorders (Wing et al., 2002).  
In addition, for a third case-control study, we recruited 16 male ASD patients and 
150 non-ASD male controls from Jeonju University Hospital in Korea. For a fourth study, 
we recruited 252 families from the Autism Genetic Resource Exchange 
(http://www.agre.org; AGRE cohort; Geschwind et al., 2001). Additional selection 
criteria required that (i) there be no possible non-idiopathic autism flags and (ii) all the 
trios be Whites, with the exclusion of Hispanic and Latino races (Anita et al., 2008). Seven 
Russian male patients from Krasnoyarsk State Medical University Hospital, and 4 
lymphoblastoid cells from Italian male ASD patients from Trino University Medical 
Hospital were also included in the study. These subjects met the DSM-IV or ADI-R criteria 
for autistic disorder. 
 For the HFA group, the U.S. autistic offspring of 104 trios (patient plus two 
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parents) among the 252 AGRE trios, who had IQ>70, were considered. In the 2nd cohort, 
we selected 188 trio families as Japanese HFA cases (Table 1). 
 Using the Autism-Spectrum Quotient (AQ) (Baron-Cohen et al., 2006; Munesue 
et al., 2008), we evaluated members of families in which older subjects performed 
self-evaluation by recalling how they behaved in their 20s. Subjects of autism traits in 3 
kindreds was defined by AQ scores, above the average (>27) but less than the higher 
level (<32), during interviews by two psychiatrists. 
This study was approved by the ethics committees of Kanazawa University, 
Hamamatsu Medical University, University of Tokyo, Osaka University, RIKEN, and the 
other participating institutes.   
 
2.3. Marker selection  
The genomic structure of CD38 is based on the University of California, Santa 
Cruz, March 2006 draft assembly of the human genome (http://www.genome.ucsc.edu). 
We selected SNPs using information from the International HapMap Project 
(http://www.hapmap.org) and the National Center for Biotechnology Information 
(NCBI dbSNP: http://www.ncbi.nlm.nih.gov/SNP). Initially, all the SNPs with 
MAF>0.1 were selected. Tags, which could capture the common allelic variants with 
r2>0.8 by pair-wise tagging, were picked from this set using Haploview v4.0 
(http://www.broad.mit.edu/mpg/haploview). 
 
2.4. Genetic analysis 
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We isolated genomic DNA from venous blood samples using the standard 
phenol/chloroform method (Easy-DNA kit; Invitrogen, Tokyo, Japan). We amplified CD38 
exons (Tables 2 and 3) and flanking introns (Table 3) by PCR (Taq PCR Core Kit; Qiagen, 
Hilden, Germany). We used Assay-on-Demand SNP genotyping products (Applied 
Biosystems, Foster City, CA) to score SNPs based on the TaqMan assay method described 
previously (Anitha et al., 2008). An ABI 7900 Sequence Detection System (SDS) was used 
to determine genotypes and analyses were performed with SDS v2.0 software (Applied 
Biosystems). Fig. 2A shows the SNPs and mutations analyzed in this study and their 
locations.  
 
2.5. Enzyme immunoassay for OT and vasopressin  
Blood samples for measuring OT and vasopressin concentrations were collected 
in two hospitals in the Kanazawa area between 10:00 and 12:00 or 15:00 and18:00 o’clock 
from subjects who had been asked to fast for the previous 2 h. Qualified lab technicians 
drew 10 ml of blood from an arm vein into heparinized tubes in less than 15 min. The 
samples were centrifuged at 0°C at 2,600 x g for 15 min and the plasma was separated off, 
divided into 2 tubes, and stored at -80°C. We performed the peptide assay for OT and 
vasopressin (AVP) as described previously (Jin et al., 2007; Liu et al., 2008).  
 
2.6. Statistics  
We analyzed the data using one- or two-way ANOVA, as appropriate. The criterion for 
significance in all cases was p<0.05. PedCheck program v1.1 
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(http://watson.hgen.pitt.edu) was used to identify and eliminate all Mendelian 
inheritance inconsistencies in the trio genotype data. Markers were tested for association 




3. Results  
The highest level of CD38 expression was detected in the human hypothalamus, 
and we detected substantial expression in the frontal cortex, amygdala, and cerebellum 
(data not shown). CD38 immunoreactivity was detected in the hypothalamus of the two 
Japanese brains (data not shown). In brains of samples from USA (Fig. 1), double 
immunohistochemical staining revealed high levels of CD38 immunoreactivity in many 
cells in the paraventricular nucleus of the hypothalamus and showed extensive colabeling 
with OT (Yamashita et al., 2002), while much lower CD38 expression levels and little or 
no detectable OT were observed in the insular cortex, which served as a control. These 
results suggested that CD38 may have an important role in OT release in the human 
hypothalamus, as in the mice (Jin et al., 2007; Liu et al., 2008). Based on this new 
information about the human brain, we set out to examine the human CD38 gene. 
 
3.1. Intronic SNP analysis in Japanese and U.S. subjects 
An association study for 10 intronic SNPs shown in Fig. 2 was first performed 
in a case-control study in a Japanese population (29 ASD subjects and 315 controls, the 
first cohort in the Table 1). No significant association with ASD was found for these 
SNPs (data not shown).  
Next, we analyzed U.S. ASD DNA samples (cohort 4). FBAT was performed for 
the whole set of 252 trios in the AGRE samples. Again, none of the SNPs showed 
significant associations, except rs3796863 (SNP06) with a tendency toward association 
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(p=0.088; Table 4). Therefore, we further analyzed this SNP for the U.S. HFA subgroup of 
104 trios in our AGRE samples (cohort 4). In the FBAT of HFA trios, rs6449197 (p=0.040) 
and rs3796863 (p=0.005) showed significant associations; a tendency for association 
(p=0.053) was found after multimarker testing (Table 4).  
Unlike the U.S. cases, no association was detected in 188 Japanese HFA trio 
cases selected from cohort 2 (p=0.228). 
One-way ANOVA showed a significant variation in the distribution of 
ADI-R_C scores (restricted, repetitive, and stereotyped patterns of behavior) between the 
C/C, C/A, and A/A genotypes of SNP06 of CD38, in 252 trios (p=0.013) and HFA trios 
(p=0.0067)  (Fig. 3). Following post hoc pairwise comparison with the Bonferroni 
method, the variations in the distribution of ADI-R_C between the C/C and C/A groups 
were found to be significant at the 0.05- and 0.01-levels, in the 252 and HFA trios, 
respectively.  
     Linkage disequilibrium (LD) analysis identified three haplotype blocks across 
the CD38 gene in 104 trios in AGRE samples, with the first block comprising SNPs01-05, 
the second block comprising SNPs06 and 07, and the third block comprising SNPs08 and 
09 (Fig. 4). The results of haplotype transmission disequilibrium test (TDT) for the HFA 
trios are shown in Table 5. The associations of haplotypes in the three haploblocks were 
examined based on the LD structure of CD38. The 1st haploblock including SNPs01-05, 
showed a weak tendency for association (p=0.055; Table 5). The haplotypes GGCAG 
(p=0.022) and GGTAG (p=0.034) of this block showed significant associations; however, 
this was not significant by permutation (permutation p=0.157 for GGCAG and 
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permutation p=0.271 for GGTAG). The GGCAG haplotype, with the C allele of SNP03, 
showed overtransmission (62.61%). Overtransmission (51.58%) of the C allele of SNP03 
was also observed in single SNP TDT.    
The 2nd haploblock including SNPs06 and 07, showed a strong association 
(p=0.001) in the HFA subgroup (Fig, 4 and Table 5). In this block, the haplotypes AT 
(p=0.015) and CT (p=0.0007) showed significant associations; the association shown by 
CT remained significant (permutation p=0.005), while that of AT was not significant 
(permutation p=0.12), by permutation. There was an overtransmission (69.18%) of the 
CT haplotype, with the C allele of SNP06. The C allele of SNP06 also showed 
overtransmission (54.52%) in single SNP TDT. 
The haplotypes of the 3rd haploblock, which included SNPs 08 and 09, did not 
show any association with HFA. None of the haplotypes in the 252 trios showed 
significant association. 
 
3.2. Mutation analysis 
Next, we performed mutation and/or exonic SNP analysis in CD38 (Fig. 2A) in 
cohort 1. The C3139T polymorphism in exon 1 led to an arginine-to-cysteine substitution 
at codon 47, the C4693T (rs1800561) polymorphism in exon 3 that led to an 
arginine-to-tryptophan substitution at codon 140 (R140W), and the C6900T 
polymorphism in exon 7 led to a serine–to-leucine substitution at codon 264. Two others 
mutations [C4092T (SNP14) and A5346C (rs1800051)] were synonymous.  
A weak association was detected for rs1800561 (R140W) in adult ASD patients 
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(average age = 22.8 ± 7.6 years old; allele frequency = 0.052) compared with controls 
(average age 34.1 ± 4.3 years old; allele frequency = 0.006) (p<0.05) in cohort 1. 
Therefore, we focused only on the rs1800561 (R140W) polymorphism in case-control 
cohort 2 (Table 1) from 3 Japanese sites and genotyped in the same platform. Of 301 
Japanese ASD subjects with the average age of 11.9 ± 6.7 years old, 13 male (but no 
female) patients were heterozygous for R140W (allelic frequency, 0.022). In 417 
unscreened control subjects without ASD, 10 males and 7 females were heterozygous for 
the mutation and one female was homozygous (allelic frequency, 0.023). We failed to 
replicate the association in the larger sample set (cohort 2) (χ2=1.20, p<0.3). Furthermore, 
although we detected the SNP in 5 of the 150 Korean controls, it was not detected it 
among the 16 Korean patients (cohort 3 in Table 1) or the 263 Caucasian patients (cohort 
4 in Table 1).  
 
3.3. rs1800561 (R140W) SNP in families 
In the course of our studies of the rs1800561 SNP (R140W), we identified three 
families (cohort 1) in which ASD appeared to relatively segregate as a dominant trait (Fig. 
5). In these families, fathers, brothers, and other relatives of 3 probands (two autistic 
(2-II-1 and 3-III-2) and one Asperger (1-III-1)) showed clinically-identified ASD or 
exhibited ASD traits. AQ scores for the brothers of two probands (1-III-2 and 3-III-1) 
fulfilled the criteria (score >28) for ASD (Asperger). 
Twenty-eight family members were available (Fig. 5, not all are shown), and 
the R140W heterozygous SNP was found in 18 subjects whose ages ranged from 22 to 86 
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years old. Out of them, 8 carriers were clinically diagnosed as ASD or with ASD traits 
(44%). In these pedigrees, no ASD subjects were found without this mutant SNP.  
Next, we examined whether mRNA from the mutant allele is expressed in the 
patients. We prepared blood RNA samples from one subject with the C/C genotype and 3 
subjects with C/T genotype. cDNA with 4693C has the MspA1I restriction site. The 
RT-PCR products from homozygous 4693C/C and heterozygous C/T subjects were 
digested by MspA1I. RT-PCR products from the C/C subject gave two (digested) bands, 
while those from the C/T subjects gave 3 bands with an additional undigested one (data 
not shown). Furthermore, sequencing of RT-PCR products of the C/T samples confirmed 
the existence of the SNP. These results show that the mutant (W140) allele was transcribed 
and expressed in the 3 probands.  
 
3.4. Plasma OT and vasopressin levels 
Plasma OT levels of ASD probands with the W140 allele (79.3 ± 14.9 pg/ml; n = 
3) were significantly lower than those of ASD subjects without the W140 allele in cohort 
1 (147.7 ± 15.0 pg/ml; p<0.01, n = 26; Fig. 6). The OT levels in ASD patients with the 
W140 allele were significantly lower than those in control subjects with the R140 allele 
(198.2 ± 24.7 pg/ml; n = 100; p<0.01). Only one control subject with the W140 allele was 
available for plasma OT measurement, and the value was 174.7 pg/ml. The OT levels in 
ASD patients with the R140 allele were almost equivalent to those in control subjects 
with the R140 allele, suggesting that allele (C/T) status may be a unique determinant for 
the plasma OT level among multiple confounding factors. In contrast, plasma AVP levels 
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were slightly higher in the probands with the W140 allele than in ASD patients with the 
R140 allele (38.9 ± 3.8 pg/ml, n = 3, vs 26.9 ± 5.0. pg/ml, n = 26; p<0.05) (Fig. 6).  
     Finally, one proband (3-III-2) aged 23 years, diagnosed with autism at the age of 3 
years and 9 months, began nasal OT administration twice a day at home with parental 
assistance in June 2008. The immediate effect of OT was obvious after the first trial, in 
which he was no longer boisterous after awaking early in the morning. This quieting on 
awaking has been maintained for more than 20 months. He showed improvements in eye 
contact behavior with smiling and answering to yes/no questions in his daily life. There 




Here, we demonstrated that one rs3796863 (C>A) SNP of CD38 showed 
significant association with U.S. but not Japanese high-fiunctioning autism (HFA) 
patients, with a cutoff at IQ>70. Based on the results of SNP- and haplotype-TDT 
analyses, the A allele of rs3796863 of CD38 may be considered a protective allele and the 
C allele as a risk allele for U.S. HFA cases. As the allele frequency is about 0.3, this 
variant is common. Very recently, common variants on 5p14.1 between neural cadherin 
10 and 9 have been reported to associate with ASD (Wang et al., 2009). As rs3796863 is 
an intronic SNP, the functional importance of this SNP remains to be determined. There 
were significant variations in the distribution of ADI-R_C scores (restricted, repetitive, 
and stereotyped patterns of behavior) between the C/C, C/A, and A/A genotypes of this 
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SNP in 252 trios and HFA trios. The second haploblock of CD38, which included 
rs3796863, showed a significant association with HFA. The association shown by the CT 
haplotype of second haploblock remained significant by permutation analysis. This 
common variant (Arking et al., 2008) may contribute to the genetic susceptibility of HFA, 
in addition to other susceptiblity genes for HFA (Weiss et al., 2009; Wermter et al., 2009). 
     SNP (rs1800561) of CD38 was reported in Japanese (allele frequency, 0.035) and 
Han Chinese (0.01) but not in European or African control populations in the online SNP 
database. However, recently, it was detected in Polish Caucasians, where 3 healthy 
controls out of 500 yielded an allele frequency of 0.003, and 21 W140 carriers were 
found among 439 B-cell chronic leukocytic leukemia patients (frequency, 0.024) 
(Jamroziak et al., 2009). An Italian study indicated one carrier among 25 healthy controls 
(frequency, 0.02; cohort 4) (Mallone et al., 2001). We found 68 carriers of the T genotype 
among 1384 Japanese, and they included controls, ASD patients, and family members of 
ASD patients. We also detected this genotype in 5 of 150 Koreans non-ASD controls with 
diabetes (frequency, 0.017; cohort 3) (Table 1), indicating that the polymorphism is more 
common among Asians than Caucasians.  
 The biological relevance of the inheritance patterns of the R140W allele was 
unclear in the context of ASD. The male offspring of W140 carriers seem to have a higher 
risk of ASD than females. Why the effect of the W140 variant on development of ASD 
varies with sex is unknown, but females may have more protective factors and/or weaker 
risk factors related to female hormones or OT. Plasma OT levels were lower in W140 
allele ASD carriers than R140 ASD carriers. However, taking into account the results that 
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the W140 allele is not associated with ASD in general population, we can only say that 
the W140 allele is deemed to have a role in decreased plasma OT levels, but not in AVP 
levels, regardless of disease status. This scenario is expected from our prior observation 
in Cd38 knockout mice (Jin et al., 2007), in which the plasma OT but not AVP level was 
differentially decreased. 
Our finding that one proband (3-III-2 in Fig. 5) with the W140 allele had been 
receiving intranasal OT was unexpected. His social behavior showed some improvement 
after the first administration of OT, and this improvement has been maintained for more 
than 20 months. The observed effects are in accordance with those reported previously 
for OT: improved mind- or emotion-reading and social memory, increased eye contact, 
and positive communication (Hollander et al., 2007; Dome et al., 2007; Guastella et al., 
2008a and b, 2009). However, to our knowledge, this is the first report of a long-term 
therapeutic effect of OT on the social deficits in ASD, suggesting that it may benefit a 
broader group of patients, disorders, or typical adults and individuals carrying this rare 
allele.  
We conducted a preliminary structural analysis of CD38 and various mutant 
proteins by Dyndom and MD simulation to analyze domain motion (Hayward and Lee, 
2002) (Fig. 7). W140-CD38 had a completely different conformation than R140-CD38 
(Fig. 7A and B). The charge change at the packed site caused by the R→W substitution 
was likely the primary reason for the outward conformation of the mutant protein. The 
mutant structure is more open and has a slightly larger degree of variation (Fig. 7C and E). 
Fig. 7D shows the solvent-accessible surface area of the active site of the mutant protein 
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altered by the closure motion, significantly changing its properties. Thus, W140 CD38 
showed changes that may affect the substrate binding affinity and eventually enzyme 
activity. The amino acid substitution can cause severe perturbations of the predicted 
protein structure in comparison with wild-type human (R140), rabbit (K140), and mouse 
(G140) CD38. In CHO cells, in fact, the W140-CD38 protein possesses only one third of 
the ADP-ribosyl cyclase activity of R140-CD38 (Yagui et al., 1998). Moreover, social 
amnesia was not rescued by local re-expression of human W140-CD38 in the 
hypothalamus in the Cd38 null mice (Jin et al., 2007). Taken together, these observations 
indicate functional abnormality of W140-CD38. 
In conclusion, despite their statistical limitations, our results suggest that the 
rs3796863 SNP may contribute to genetic susceptibility to HFA in U.S. but not 
necessarily in Japanese subjects (at least to the limits of our current analysis). Our result 
call for functional and expression assay to assess the biological effects of the variant. 
Furthermore, the W140 allele could be a potential risk factor for a subset of Japanese 
ASD patients, i.e., males with low blood OT levels. Patients in this subgroup are 
candidates for a clinical trial of OT treatment, although further systematic case-control 
investigations are required to verify its effects.  
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Fig. 1. Immunohistochemical analysis of CD38 and oxytocin in the human brain. Cell 
montages of panels were taken from the paraventricular nucleus (PVN) in the 
hypothalamus (A to C) and insular cortex (D to F) of autopsy subjects from the USA. 
Arrow heads indicate extensive colabeling with OT. The insets in panels are enlarged 
images of neurons showing coexpression of CD38 and OT. Scale bars: 40 µm in C and 8 
µm in insert. 
 
Fig. 2. Genome structure, SNPs, and mutations of CD38. (A) Genomic structure of CD38 
and locations of SNPs in introns (upper) and mutations in exons (lower). Exons are 
indicated by boxes, with translated regions in closed boxes and untranslated regions in 
open boxes. Numbering of the nucleotides starts at the A of ATG and refers to GenBank 
Accession number D84284. (B) The sequence trace was derived from a DNA sample of a 
4693C/T heterozygote. (C) Amino acid sequence of CD38 showing conservation of R at 
the 140th amino acid among different species, except for rodents and rabbits. Sequences 
were obtained through the accession numbers NM001775, AY555148, NM175798, 
AF117714, AF272974, NM013127, NM007646, D30048, and M85206/M37644 for the 
indicated species.  
 
Fig. 3. Comparison of the distribution of ADI-R_C scores of autistic individuals across the 
C/C, C/A, and A/A genotypes of rs3796863 in 252 trios (A) and HFA trios (B). Significant 
variation was observed in the distribution of ADI-R_C scores between the three groups, in 
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the 252 trios and HFA trios. The variation in the distribution of ADI-R_C between the C/C 
and C/A groups was significant at the 0.05- and 0.01-levels in the 252 and HFA trios, 
following post hoc pairwise comparison with Bonferroni’s method. One-way analysis of 
variance (ANOVA), followed by post hoc pairwise comparison with Bonferroni’s test, was 
used to examine the variability in the distribution of ADI-R phenotypic data (ADI-R_A, 
ADI-R_BV, ADI-R_C, ADI-R_D) across the homozygous and heterozygous genotypes of 
SNPs that showed significant associations in single SNP TDT. 
 
Fig. 4. LD structure of CD38 based on D’ values calculated from HFA trios. 
A linkage disequilibrium (LD) plot was constructed using the D’ (linkage disequilibrium 
coefficient; Ranade, 2001) pairwise LD values between markers, estimated using the 
Haploview software. Based on the LD structure of the gene, haplotype associations were 
examined; all the haplotypes with frequency >0.01 were included for the association test. 
 
 
Fig. 5. Pedigrees of the 3 ASD probands carrying the W140 allele. Squares and circles 
represent male and female family members, respectively. Black squares represent those 
with ASD or ASD trait. A slash mark through symbols indicates the subject is deceased. 
The allele status is indicated under the symbols: N/N, two normal alleles; R140W/N, one 
mutant and one normal allele. Gray symbols indicate undetermined (no DNA available for 
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analysis). The subjects are identified by Arabic numbers, and the generation by roman 
numbers. The arrow indicates the proband. *, Autism trait; #, Autism; A, Asperger. 
 
Fig. 6. Plasma oxytocin and vasopressin levels in ASD subjects. Bar graph (A) and 
Scatchard plot (B) of plasma concentrations of OT and AVP levels in 29 ASD patients in 
cohort 1 with (red) or without (green) the W140 allele. Mean ± s.e.m. *, p < 0.05; **, p < 
0.01 (one-way ANOVA).  
 
Fig. 7. Molecular structure of CD38. The interactions between R140 (A) or W140 (B) and 
nearby residues in CD38 protein are shown. Hydrogen bonds are shown as dashed lines. 
The protein residues are colored as follows: C, blue except the 140 residue (yellow); N, 
blue; O, red. R140 and W140 are packed into the helix, and the packing conformation 
seems stable. The W140 protein has an outward conformation and fewer interacting 
residues than the wild-type protein. (C) Distribution of distance and angle between 
domains. The distance between Q171 and S213 and the angle between Q171, G113 (hinge), 
and S213 are plotted based on domain analysis. The R140 structures are shown as black 
dots and the W140 as red dots. Each point representing a conformation is from MD 
simulation (5-9ns). The mutant structure has a more the open conformation than the 
wild-type and a slightly larger degree of variation. (D) Solvent-accessible surface areas. 
The active site properties are significantly different between the mutant and wild-type. (E) 
Distribution of distance and angle between domains during 5-9 ns MD simulation as in 
(C): R140, black; W140, red; K140, green; and G140, blue. K140 shows almost the same 
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 Table 1 
 Data sets for the 4 case-control study cohorts. 
 
Data set*   Cohort 1   Cohort 2                 Cohort 3       Cohort 4 
Subjects Age (Range) Male/Female      Subjects Age (Range) Male/Female    Subjects  Subjects Male/Female 
Cases (Probands)   29  22.8 ± 7.6 (12-44) 23/6   301  11.9 ± 6.7 (3-64) 263/38.        16   263  263/0 
Controls  315  34.1 ± 4.3 (8-75) 171/144         417  28.6 ± 14.4 (5-65) 229/188      150   - 
Trio families    3   334     252 
Family member  25  53.0 ± 4.5 (21-84) 15/10     297  39.2 ± 15.5 (3-93) 143/154        -     -  
HFA subjects   -              188     104 
Usage/analysis Intronic SNP   -           -        Intronic SNP   
Exonic mutation  R140W           R140W  R140W  
Family-based associatio  HFA association    HFS association 
OT/AVP measurement 
*Cohort 1 was from the Kanazawa area, Japan; Cohort 2, the Nagoya/Hamamatsu, Tokyo, and Osaka areas, Japan;  
Cohort 3, Jeonju, Korea; Cohort 4, study of 252 trio samples from the Autism Genetic Resource Exchange comprising 252 U.S., 7  
Russian, and 4 Italian ASD patients.  Age ± SEM years, (Year range). 
Table 2 
Oligonucleotides. Designed for amplification of coding sequences including 60–100 bp of flanking intronic sequences. Primers were 
followings:  
 
Exon  Up     Down 
 
1  5’-AGGGAAACAGAGAAAAGGCAAGTGU 5’-GGCCAGCTGCTCCTGAAAG-3’   
2  5’-GGCATATAATAGATGCTTCC-3’   5’-TGGACCTATGAATTGTTACC-3’  
3 5’-GACATGCTAAATTGATCTCAG-3’  5’-CAGCAGAAGTCACTCTGTTC-3’    
4   5’-TCCACTATGACTGAACAGCC-3’  5’-AGCACTGACTGAGTAACG-3’   
5   5’-CTTAACCAGCTATTGCTAAG   5’-ACTGTGATATTTGCAACAGG-3’    
6  5’-TCTGCCTGCTGGTTGTTGAG-3  5’-TCCTGAGTCAATTTGTTCCC-3’  
7  5’-CCCAACAGCCTCTTAACTTT-3’  5’-ATCACCAGAGGTTGCCAT-3’  
8  5’-AGCGAATTGGACGACAGATG-3’ 5’-CATTGACCTTATTGTGGAGG-3’  
  
Usually, we used the following temperatures: 15 min at 95 °C, 35 cycles of 30 s at 95 °C, 30 s at annealing temperature at 52 °C, 5 min 





Table 3   
Sequence information for SNPs1-10 and R140W. 
 
SNP   Sequence       Strand ON GENE UCSC NO 
 
SNP01 (rs3796878)  TTGCTCTGTTCCCAGGTTGGTCCTCC[A/G]CATACCTCCCACTGCAGGATCCTGG     - T/C 15,394,757 
SNP02 (rs3796875) GTTTTTCAAGAGTCCTAAGACAAAGA[A/G]GAAAGGAAGAAGCAGAGAAGCCATG     - T/C 15,396,312 
SNP03 (rs6449197) CAGGTTGAGGAAATTTTATTTCTAAT[C/T]TGCTCAGTGTTTTTTTCATCACAAG     + C/T 15,424,020 
SNP04 (rs11574927) AAAATTGTGTACCCCAATTCAGTAGT[A/G]AAACTACTACCGGGAACATCGGGAA     + A/G 15,449,341 
SNP05 (rs10805347) ATTAACATTTCAGAATTTTATGATCT[A/G]ATATTATGGTTCAAGCACTTGAAAC     + A/G 15,449,937 
SNP06 (rs3796863) GGGAGGGGAGCTATCCATGCCACCTG[A/C]TGGTCAAAAAAACAGCAGGAGCAGC     - T/G 15,459,084 
SNP07 (rs1130169) TGTACCCTTCCT ACAGATAGTCAAAC[C/T]ATAAACTTCATGGTCATGGGTCATG     + C/T 15,459,783 
SNP08 8rs13137313) AAATAAACCATATGTGTTGAACAAAG[A/G]ATTAATAAATTAATTTGAGACTCAA      + A/G 15,461.066  
SNP09 (RS3733593) ATCTTGAACAAAATCGCCTAACCTTTC[C/T]GAACTTCAACTTCCTTGCCACTCCT     + C/T 15,461,202 
SNP10 (rs3733593) CTGCCTCCGAATTCCATAGTTTCCAC[C/T]GCCTTGCGCTACTTGCATTCTCTGATT     - G/A 15,463,823 
R140W (rs1800561) TGGCCCATCAGTTCACACAGGTCCAG[C/T]GGGACATGTTCACCCTGGAGGACAC     + C/T 15,435,656 
Table 4   FBAT analysis of CD38 SNPs in AGRE trios 
 
Marker Allele 252 trios     HFA trios 
 
  Families* Frequency Z-score p-value  Families* Frequency Z-score p-value† 
 
rs3796878 A 119 0.163 0.253 0.801  49 0.161 0.640 0.522 
 G 119 0.837 -0.253   49 0.839 -0.640  
rs3796875 A 171 0.659 -0.740 0.459  78 0.640 -0.594 0.552 
 G 171 0.341 0.740   78 0.360 0.594  
rs6449197 T 79 0.103 -0.647 0.518  30 0.103 -2.058 0.040 
 C 79 0.897 0.647   30 0.897 2.058  
rs11574927 A 111 0.830 0.947 0.344  55 0.834 1.861 0.063 
 G 111 0.170 -0.947   55 0.166 -1.861  
rs10805347 A 171 0.321 -0.614 0.539  71 0.309 -0.663 0.508 
 G 171 0.679 0.614   71 0.691 0.663  
rs3796863 A 160 0.277 -1.706 0.088  74 0.270 -2.800 0.005 
 C 160 0.723 1.706   74 0.730 2.800  
rs1130169 T 195 0.503 1.004 0.315  85 0.517 0.659 0.510 
 C 195 0.497 -1.004   85 0.483 -0.659  
rs13137313 A 168 0.742 0.765 0.445  72 0.726 0.426 0.670 
 G 168 0.258 -0.765   72 0.274 -0.426  
rs17476066 T 167 0.714 0.697 0.486  69 0.714 0.655 0.513 
 C 167 0.286 -0.697   69 0.286 -0.655  
rs3733593 T 178 0.451 0.962 0.336  74 0.428 0.887 0.375 
 C 178 0.549 -0.962   74 0.572 -0.887  
 
p-value after multimarker testing   0.295     0.053 
 
* Informative families.  † Significant p-values are indicated in bold italic. 
Table 5 
Haplotype associations of SNPs belonging to the three LD blocks of CD38 in HFA trio 
Block  Haplotype* Frequency T (%) Individual  Permutation ** Block  
       p-value  p-value** p-value 
Block 1 (SNPs 1-5) 
  GACAA  0.304  49.41 0.914  1 
  GGCAG  0.248  62.61 0.022  0.157 
  GACGG  0.163  39.68 0.102  0.565  0.055 
  AACAG  0.153  54.39 0.508  0.998 
  GGTAG  0.099  31.25 0.034  0.271 
  GACAG  0.02  62.65 0.456  0.994 
Block 2 (SNPs 6-7) 
  CC  0.476  48.69 0.781  1 
  AT  0.287  37.05 0.015  0.12  0.001 
  CT  0.23  69.18 0.0007  0.005 
Block 3 (SNPs 8-9)  
AT  0.441  54.53 0.351  0.979 
  AC  0.286  46.7 0.543  0.999  0.638 
  GT  0.274  47.73 0.67  1 
T (%): Transmitted/(Transmitted +Untransmitted). *All possible combinations of haplotypes with frequency >0.01.  


























































































































   1 R140W/N            2 N/N         3 R140W/N                   
          1 R140W/N  2 R140W/N  
                                          3 R140W/N 4 R140W/N 
                1  N/N                 2 R140W/N                               1 R140W/N        2 N/N
 1 R140W/N    2                3                  1 R140W/N       2 N/N      3 N/N    4 R140W/N 
   1 R140W/N  2 R140W/N   3            
Family #3
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